ClinicalTrials.gg
TerminatedNCT05132075KontRASt-02Updated Nov 6, 2026

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

A Phase 3 interventional study of JDQ443 and docetaxel in Non-Small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 51 sites in 25 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Business reasons and not based on any safety concerns.
Updated Nov 6, 2026Now TerminatedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis — 7 open to participants now, 15 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Novartis.

Enrollment
45th of 92
95 · median 91
Started
2022
with 6 others
Phase 3
15 of 101
none open now
Registered
85th of 101
by date

Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is the 45th largest by enrollment of the 92 interventional ones that give a count, is one of 7 that started in 2022, is one of 15 in phase 3, and was the 85th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, or all of them as a file.
02

Study summary

This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.

Read the detailed description

The study was designed as a multi-center, open-label, randomized, active-controlled, Phase III trial.

Participants were randomized to either JDQ443 or docetaxel. Participants randomized to the docetaxel arm had the opportunity to cross over to JDQ443 at disease progression per RECIST 1.1 by local investigator assessment.

The study population included adult participants with locally advanced or metastatic (stage IIIB/IIIC or IV) KRAS G12C mutant non-small cell lung cancer (by tissue or plasma as determined by a Novartis-designated central laboratory or accepted local tests) who had received prior platinum-based chemotherapy and prior immune checkpoint inhibitor therapy administered either in sequence or as combination therapy.

Approximately 360 participants were planned to be randomized to JDQ443 or docetaxel in a 1:1 ratio stratified by prior line of therapy and ECOG performance status. Following the decision to halt enrollment for business reasons, a total of 95 participants were randomized.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • NSCLC
  • Non small cell lung cancer
  • Lung cancer
  • Cancer of the lung
  • Cancer of lung
  • Pulmonary Cancer
  • Neoplasms, Lung
  • Neoplasms, Pulmonary
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has confirmed locally advanced/ (stage IIIB/IIIC or IV)
  • Participant has a KRAS G12C mutation present in tumor tissue or plasma prior to enrollment, as determined by a Novartis designated central laboratory or by accepted local tests.
  • Participants has received one prior platinum-based chemotherapy regimen and one prior therapy for locally advanced or metastatic disease
  • Participant has at least 1 evaluable (measurable or non-measurable) lesion by 1.1 at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • Participants who have previously received docetaxel (except if received in or adjuvant setting with no progression within 12 months after the of end of treatment), or any other KRAS G12C inhibitor.
  • Participant has EGFR-sensitizing mutation and/or ALK rearrangement by local laboratory testing. Participants with other druggable alterations will be excluded if required by local guidelines.
  • Participant has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Participant has an history of interstitial lung disease or pneumonitis grade > 1.

Other inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    JDQ443

    Participants treated with JDQ443

    Drug: JDQ443

  • Active comparator
    Docetaxel

    Participant treated with docetaxel following local guidelines as per standard of care and product labels

    Drug: docetaxel

Interventions

  • DrugJDQ443

    JDQ443 tablets, orally administered

  • docetaxel concentrated solution for infusion, intravenously administered

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    PFS is the time from date of randomization to the date of event defined as the first documented disease progression based on local Investigator assessment per RECIST 1.1 criteria or death due to any cause.

    Time frame: Approximately up to 24 months

Secondary outcomes

  1. Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs (any AEs regardless of seriousness) and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.

    Time frame: Approximately up to 25 months

07

Study locations

51 sites
  • Valley Medical Center Research
    Renton, Washington 98055, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1414DRK, Argentina
  • Novartis Investigative Site
    Pilar, Buenos Aires B1629AHJ, Argentina
  • Novartis Investigative Site
    Auchenflower, Queensland 4066, Australia
  • Novartis Investigative Site
    South Brisbane, Queensland 4101, Australia
  • Novartis Investigative Site
    Montreal, Quebec H4A 3J1, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Novartis Investigative Site
    Fuzhou, Fujian 350014, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
  • Novartis Investigative Site
    Harbin, Heilongjiang 150081, China
  • Novartis Investigative Site
    Changsha, Hunan 410013, China
  • Novartis Investigative Site
    Shengyang, Liaoning 110042, China
  • Novartis Investigative Site
    Jinan, Shandong 250117, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Turku, 20521, Finland
  • Novartis Investigative Site
    Athens, GR 115 27, Greece
  • Novartis Investigative Site
    Athens, 115 26, Greece
  • Novartis Investigative Site
    Heraklion Crete., 715 00, Greece
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Kowloon, 999077, Hong Kong
  • Novartis Investigative Site
    Budapest, 1121, Hungary
  • Novartis Investigative Site
    Reykjavik, 101, Iceland
  • Novartis Investigative Site
    Jaipur, Rajasthan 302019, India
  • Novartis Investigative Site
    Delhi, 110085, India
  • Novartis Investigative Site
    Lucca, LU 55100, Italy
  • Novartis Investigative Site
    Aviano, PN 33081, Italy
  • Novartis Investigative Site
    Roma, RM 00128, Italy
  • Novartis Investigative Site
    Amman, 11941, Jordan
  • Novartis Investigative Site
    Ed Daoura, 90375, Lebanon
  • Novartis Investigative Site
    Kuching, Sarawak 93586, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Mexico City, 06760, Mexico
  • Novartis Investigative Site
    Matosinhos Municipality, 4454-513, Portugal
  • Novartis Investigative Site
    Porto, 4100-180, Portugal
  • Novartis Investigative Site
    Cluj-Napoca, Cluj 400015, Romania
  • Novartis Investigative Site
    Ljubljana, Slovenia 1000, Slovenia
  • Novartis Investigative Site
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Oviedo, Principality of Asturias 33011, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Tainan, 704302, Taiwan
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Adana, Adana 01140, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Ankara 06680, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Bilkent Cankaya 06800, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Fatih 34093, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Pendik 34899, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Yenimahalle 06500, Turkey (Türkiye)
  • Novartis Investigative Site
    Hanoi, 300000, Vietnam
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Sep 2026, 50 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2021
First posted
Nov 24, 2021
StartActual
Jun 15, 2022
Primary completionActual
Sep 3, 2026
CompletionActual
Oct 5, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Business reasons and not based on any safety concerns.
changed Nov 6, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (1 Slovenia, 1 Turkey (Türkiye))
  • Novartis Investigative Site · Ljubljana, Slovenia
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Show 2 removed
  • Novartis Investigative Site · Ljubljana, Slovenia
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Nov 6, 2026
Study completion
Oct 3, 2026→Oct 5, 2026 (actual)
Nov 6, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionProgression free survival (PFS): how it is measured was reworded
Nov 6, 2026
Secondary outcomes
1 added, 14 removed
What changed in the outcomes
  • AddedNumber of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Approximately up to 25 months
  • RemovedOverall Survival (OS)Time frame: Approximately up to 33 months
  • RemovedOverall Response Rate (ORR)Time frame: Approximately up to 33 months
  • RemovedDisease Control Rate (DCR)Time frame: Approximately up to 33 months
  • RemovedTime To Response (TTR)Time frame: Approximately up to 33 months
  • RemovedDuration of Response (DOR)Time frame: Approximately up to 33 months
  • RemovedProgression-Free Survival after next line therapy (PFS2)Time frame: Approximately up to 33 months
  • RemovedConcentration of JDQ443 and its metabolite in plasmaTime frame: Approximately up to 33 months
  • RemovedTime to definitive deterioration of Eastern Cooperative Group of Oncology Group (ECOG) performance statusTime frame: Approximately up to 33 months
  • RemovedTime to definitive 10-point deterioration symptom scores of chest pain, cough and dyspnea per QLQ-LC13Time frame: Approximately up to 33 months
  • RemovedTime to definitive 10-point deterioration in global health status/QoL, shortness of breath and pain per QLQ-C30Time frame: Approximately up to 33 months
  • RemovedChange from baseline in EORTC-QLQ-C30Time frame: Approximately up to 33 months
  • RemovedChange from baseline in EORTC-QLQ-LC13Time frame: Approximately up to 33 months
  • RemovedChange from baseline in EORTC-EQ-5D-5LTime frame: Approximately up to 33 months
  • RemovedChange from baseline in NSCLC-SAQTime frame: Approximately up to 33 months
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Terminated
    Why stopped Business reasons and not based on any safety concerns.
    2 sites added, 2 sites removed
    Show 2 added (1 Slovenia, 1 Turkey (Türkiye))
    • Novartis Investigative Site · Ljubljana, Slovenia
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 2 removed
    • Novartis Investigative Site · Ljubljana, Slovenia
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Study completion Oct 3, 2026→Oct 5, 2026 (now actual)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionProgression free survival (PFS): how it is measured was reworded
    Secondary outcomes 1 added, 14 removed
    What changed in the outcomes
    • AddedNumber of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Approximately up to 25 months
    • RemovedOverall Survival (OS)Time frame: Approximately up to 33 months
    • RemovedOverall Response Rate (ORR)Time frame: Approximately up to 33 months
    • RemovedDisease Control Rate (DCR)Time frame: Approximately up to 33 months
    • RemovedTime To Response (TTR)Time frame: Approximately up to 33 months
    • RemovedDuration of Response (DOR)Time frame: Approximately up to 33 months
    • RemovedProgression-Free Survival after next line therapy (PFS2)Time frame: Approximately up to 33 months
    • RemovedConcentration of JDQ443 and its metabolite in plasmaTime frame: Approximately up to 33 months
    • RemovedTime to definitive deterioration of Eastern Cooperative Group of Oncology Group (ECOG) performance statusTime frame: Approximately up to 33 months
    • RemovedTime to definitive 10-point deterioration symptom scores of chest pain, cough and dyspnea per QLQ-LC13Time frame: Approximately up to 33 months
    • RemovedTime to definitive 10-point deterioration in global health status/QoL, shortness of breath and pain per QLQ-C30Time frame: Approximately up to 33 months
    • RemovedChange from baseline in EORTC-QLQ-C30Time frame: Approximately up to 33 months
    • RemovedChange from baseline in EORTC-QLQ-LC13Time frame: Approximately up to 33 months
    • RemovedChange from baseline in EORTC-EQ-5D-5LTime frame: Approximately up to 33 months
    • RemovedChange from baseline in NSCLC-SAQTime frame: Approximately up to 33 months
    + 4 other changes: identifiers, verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05132075
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Jun 15, 2022
Primary completion
Sep 3, 2026
Completion
Oct 5, 2026
Last update
Nov 6, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JDQ443

Start the discussion